Keros Therapeutics, Inc. (NASDAQ:KROS) Sees Large Growth in Short Interest

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 4,260,000 shares, a growth of 6.0% from the January 15th total of 4,020,000 shares. Based on an average daily trading volume, of 1,500,000 shares, the days-to-cover ratio is currently 2.8 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC grew its position in shares of Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company's stock worth $284,493,000 after purchasing an additional 179,374 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Keros Therapeutics by 5.4% during the 4th quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock worth $30,981,000 after acquiring an additional 100,691 shares in the last quarter. Alkeon Capital Management LLC boosted its position in shares of Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after acquiring an additional 298,694 shares in the last quarter. Braidwell LP boosted its position in shares of Keros Therapeutics by 167.9% during the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after acquiring an additional 1,187,199 shares in the last quarter. Finally, Darwin Global Management Ltd. lifted its stake in Keros Therapeutics by 10.7% in the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock valued at $26,707,000 after purchasing an additional 163,403 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Price Performance

Keros Therapeutics stock traded up $0.42 during trading hours on Thursday, hitting $11.03. The company had a trading volume of 891,604 shares, compared to its average volume of 1,695,745. The firm has a market cap of $446.83 million, a PE ratio of -2.12 and a beta of 1.39. Keros Therapeutics has a one year low of $9.77 and a one year high of $73.00. The firm has a 50-day moving average of $13.35 and a 200 day moving average of $41.02.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Wells Fargo & Company boosted their price target on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. Wedbush cut shares of Keros Therapeutics from an "outperform" rating to a "neutral" rating and dropped their target price for the company from $47.00 to $15.00 in a report on Friday, January 17th. Truist Financial dropped their target price on shares of Keros Therapeutics from $100.00 to $43.00 and set a "buy" rating on the stock in a report on Monday, December 23rd. Scotiabank dropped their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a report on Thursday, January 16th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Keros Therapeutics in a report on Friday, January 17th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $52.56.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.